# Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

> **NCT03755414** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 55 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndromes
- Non-Hodgkin Lymphoma
- Hodgkin Disease

## Interventions

- **PROCEDURE:** Stem cell transplantation
- **DRUG:** Itacitinib
- **OTHER:** Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)
- **OTHER:** Human Activity Profile

## Key facts

- **NCT ID:** NCT03755414
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-04
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-05-26
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755414, "Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03755414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*